MSA stands for multiple system atrophy, a progressive neurodegenerative disorder involving autonomic failure and parkinsonian and/or cerebellar features. It leads to worsening motor and autonomic dysfunction over time.
Quantitative and functional MRI techniques are gaining traction as biomarkers in neurodegenerative diseases. A consensus statement provides MRI endpoint recommendations for clinical trials in hereditary ataxias like SCA and Friedreich ataxia. Separately, research shows resting-state fMRI can distinguish subtypes of multiple system atrophy and may improve early diagnosis.
Alterity is preparing for a mid-2026 end-of-Phase II FDA meeting for ATH434 in Multiple System Atrophy. Phase II data showed clinically meaningful and statistically significant effects, with safety comparable to placebo.
NeuraLight will present a neuroprogression biomarker that outperforms the current gold standard for tracking Parkinson's disease progression at the AD/PD 2026 conference in Copenhagen beginning March 17.
iRegene Therapeutics has dosed the first U.S. patient in a Phase IIa trial of NouvNeu001 for Parkinson's disease and enrolled the first patient in a China trial of NouvNeu004 for Multiple System Atrophy.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07465198 |
Autologous Stem Cell Therapy in Patients With Multiple System Atrophy |
NOT_YET_RECRUITING | PHASE2 |
| NCT06647641 |
The CurePSP Genetics Program |
RECRUITING | |
| NCT03829657 |
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure |
TERMINATED | PHASE3 |
| NCT03033680 |
Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA |
COMPLETED | PHASE1/PHASE2 |
| NCT02315027 |
Mesenchymal Stem Cell Therapy in Multiple System Atrophy |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
